Your selection
Research, Innovation, Patient care, Education / 18.06.2025
Students from Freie Universität Berlin visited the Campus Berlin-Buch
Visiting the Campus Berlin-Buch: Master's students in Biology at Freie Universität Berlin learned about career opportunities and start-ups at the BiotechPark Berlin-Buch on June 11, 2025.
During a tour of the campus with Campus Manager Dr. Ulrich Scheller, they were first given an overview of the closely cooperating research institutions and biotech companies as well as the location of future innovation Berlin-Buch, whose profile focuses on biomedicine and health.
Dr. Uwe Lohmeier, Head of the Berlin BioScience Academy, and Trendelina Rrustemi, Senior Scientist at Alithea Biotechnology GmbH, gave an insight into their career paths at the Career Panel Talk in the BerlinBioCube start-up center building. Dr. Lohmeier explained the development opportunities offered by the Berlin BioScience Academy (BBA).
Trendelin Rrustemi presented her start-up Alithea Biotechnology GmbH. It offers pioneering HLA peptide characterization with innovative immunopeptidomics, highly sensitive mass spectrometry and applied AI.
The students were then given an insight into the start-ups CUTANEON - Skin & Hair Innovations GmbH, Cultimate Foods GmbH and FyoniBio GmbH
The BiotechPark on the Campus Berlin-Buch is one of the leading technology parks in Germany. Buch has been renowned for its clinics and cutting-edge research for around 100 years and is now one of the largest biomedical locations in Germany.
The Berlin BioScience Academy (BBA), formerly known as "Gläsernes Labor Akademie (GLA)", supports young scientists throughout Germany in their professional orientation and entry into the pharmaceutical and biotechnology industry.
www.glaesernes-labor-akademie.de
Overview News
News Buch Berlin
Promoting awareness of health research
During a week-long course at the Gläsernes Labor, 24 teenagers delved into genetics, immunology, and allergic disease. The course marked the beginning of a new collaboration with the Max Delbrück Cent...
more ...Targeting sleeping tumor cells
Neuroblastoma, a cancer mainly affecting children, is often difficult to treat. A team led by Jan Dörr and Anton Henssen at the Experimental and Clinical Research Center report in “Cancer Discovery,” ...
more ...Eckert & Ziegler Selected as US Manufacturer for Archeus’ Next-Generation Radiopharmaceutical ART-101
Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contrac...
more ...Events Buch Berlin
30.08.2025, 17:00
Blindspot-Konzert #7: WOODEN ELEPHANT – BJÖRK: Homogenic
Mit ihrer außergewöhnlichen Fähigkeit, elektronische Kultalben in akustische Klangwelten zu übersetzen, steht das internationale Streichquintett Wooden Elephant im Zentrum des kommenden Konzerts der B...
more ...09.09.2025, 09:00
From Target to Market - The BBA Biotech & Pharma Summer School
The 4-day intensive course provides a comprehensive overview of the entire drug development process in biotechnology and in the pharmaceutical industry – from the idea to the market.
more ...
